These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 2952663)

  • 1. Hyperglycemia and obesity as determinants of glucose, insulin, and glucagon responses to beta-endorphin in human diabetes mellitus.
    Giugliano D; Salvatore T; Cozzolino D; Ceriello A; Torella R; D'Onofrio F
    J Clin Endocrinol Metab; 1987 Jun; 64(6):1122-8. PubMed ID: 2952663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered metabolic and hormonal responses to epinephrine and beta-endorphin in human obesity.
    Giugliano D; Cozzolino D; Salvatore T; Torella R; Franchimont P; D'Onofrio F; Lefebvre PJ
    J Clin Endocrinol Metab; 1988 Aug; 67(2):238-44. PubMed ID: 2969000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The involvement of the opioid system in human obesity: a study in normal weight relatives of obese people.
    Cozzolino D; Sessa G; Salvatore T; Sasso FC; Giugliano D; Lefebvre PJ; Torella R
    J Clin Endocrinol Metab; 1996 Feb; 81(2):713-8. PubMed ID: 8636293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
    Knop FK; Aaboe K; Vilsbøll T; Vølund A; Holst JJ; Krarup T; Madsbad S
    Diabetes Obes Metab; 2012 Jun; 14(6):500-10. PubMed ID: 22171657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-endorphin and the endocrine pancreas. Studies in healthy and diabetic human beings.
    Feldman M; Kiser RS; Unger RH; Li CH
    N Engl J Med; 1983 Feb; 308(7):349-53. PubMed ID: 6296674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of altered metabolic responses to beta-endorphin after normalization of body weight in human obesity.
    Giugliano D; Cozzolino D; Torella R; Lefebvre PJ; Franchimont P; D'Onofrio F
    Acta Endocrinol (Copenh); 1991 Feb; 124(2):159-65. PubMed ID: 2003375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-endorphin and islet hormone release in type-2 diabetes mellitus the effects of normoglycemia, enkephalin, naloxone and somatostatin.
    Giugliano D; Cozzolino D; Salvatore T; Ceriello A; Giunta R; Torella R; D'Onofrio F
    Diabete Metab; 1987; 13(6):618-24. PubMed ID: 2896134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological elevations of plasma beta-endorphin alter glucose metabolism in obese, but not normal-weight, subjects.
    Giugliano D; Cozzolino D; Salvatore T; Ceriello A; Torella R; Franchimont P; Lefebvre PJ; D'Onofrio F
    Metabolism; 1992 Feb; 41(2):184-90. PubMed ID: 1736041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No change of beta-endorphin plasma levels during hyperglycemic glucose clamping in obese patients and lean controls.
    Ritter MM; Möhrle W; Richter WO; Schwandt P
    Horm Metab Res; 1990 Sep; 22(9):504-5. PubMed ID: 2258138
    [No Abstract]   [Full Text] [Related]  

  • 10. Beta endorphin modulation of the glucoregulatory effects of repeated epinephrine infusion in alloxan-diabetic and normal dogs.
    el-Tayeb KM; Vranic M; Brubaker PL; Lickley HL
    Diabetologia; 1987 Sep; 30(9):745-54. PubMed ID: 2962893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-endorphin infusion restores acute insulin responses to glucose in type-2 diabetes mellitus.
    Giugliano D; Ceriello A; Salvatore T; Paolisso G; D'Onofrio F; Lefèbvre P
    J Clin Endocrinol Metab; 1987 May; 64(5):944-8. PubMed ID: 2951394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of insulin on fasting and meal-stimulated somatostatin-like immunoreactivity in noninsulin-dependent diabetes mellitus: evidence for more than one mechanism of action.
    Gutniak M; Grill V; Efendić S
    J Clin Endocrinol Metab; 1986 Jan; 62(1):77-83. PubMed ID: 2866196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Plasma levels of beta-endorphin in obese subjects with normal glucose tolerance test and in diabetics].
    Donatelli M; Terrizzi C; Russo V; Bucalo ML; Scarpinato A; Verga S; Puglisi S; Miceli G; Iraci T; Bompiani GD
    Recenti Prog Med; 1991 Jan; 82(1):1-3. PubMed ID: 2028070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastric inhibitory polypeptide in obesity and diabetes mellitus.
    Service FJ; Rizza RA; Westland RE; Hall LD; Gerich JE; Go VL
    J Clin Endocrinol Metab; 1984 Jun; 58(6):1133-40. PubMed ID: 6373812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity to beta-endorphin as a cause of human obesity.
    Giugliano D; Salvatore T; Cozzolino D; Ceriello A; Torella R; D'Onofrio F
    Metabolism; 1987 Oct; 36(10):974-8. PubMed ID: 2958673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-endorphin stimulates the secretion of insulin and glucagon in diabetes mellitus.
    Reid RL; Sandler JA; Yen SS
    Metabolism; 1984 Mar; 33(3):197-9. PubMed ID: 6319955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the suppressive effects of elevated plasma glucose and free fatty acid levels on glucagon secretion in normal and insulin-dependent diabetic subjects. Evidence for selective alpha-cell insensitivity to glucose in diabetes mellitus.
    Gerich JE; Langlois M; Noacco C; Lorenzi M; Karam JH; Korsham PH
    J Clin Invest; 1976 Aug; 58(2):320-5. PubMed ID: 783198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoinsulinemic and hyperglycemic effects of beta-endorphin in rabbits.
    Knudtzon J
    Horm Metab Res; 1986 Aug; 18(8):505-9. PubMed ID: 2944808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary role of glucagon release in the effect of beta-endorphin on glucose homeostasis in normal man.
    Paolisso G; Giugliano D; Scheen AJ; Franchimont P; D'Onofrio F; Lefèbvre PJ
    Acta Endocrinol (Copenh); 1987 Jun; 115(2):161-9. PubMed ID: 2885994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.